Advanced lung cancer patients see improved, progression-free survival
Thursday, November 13, 2008 - 10:49
in Health & Medicine
Patients with advanced non-small cell lung cancer whose disease has progressed following chemotherapy have a higher rate of tumor shrinkage and a longer interval before cancer progression when bevacizumab is added to standard second-line erlotinib therapy, according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology.
Read the whole article on Physorg
More from Physorg
Related
- Advanced lung cancer patients see improved, progression-free survivalThu, 13 Nov 2008, 10:51:04 EST
- Chemotherapy plus targeted therapies shows improved survival in advance-stage lung cancer patientsThu, 13 Nov 2008, 10:51:01 EST
- Tissue analyses indicate survival benefits for some lung cancer patientsThu, 13 Nov 2008, 10:51:06 EST
- Research demonstrates differing genetic makeup of lung cancer in African-American patientsThu, 13 Nov 2008, 10:50:58 EST
- Gender is key factor in determining overall survival of lung cancer patientsThu, 13 Nov 2008, 10:51:11 EST